| WKN: | A2P4GU |
| ISIN: | US14147L1089 |
| Land: | USA |
| Branche: | Chemie, Pharma, Bio- & Medizintechnik |
| Sektor: | Biotechnologie |
Weshalb die Cardiff Oncology-Aktie
ein D-Rating hat,
erfahren Sie im Performance-Check
vom 16. November 2025 Info.
| Rang | Datum | Vorjahr | Schluss | Performance |
|---|---|---|---|---|
| 1 | 2024 | 1,27 | 4,05 | 218,90% |
| 2 | 2015 | 259,70 | 365,26 | 40,65% |
| 3 | 2023 | 1,25 | 1,27 | 1,60% |
| 4 | 2014 | 305,71 | 259,70 | -15,05% |
| 5 | 2025 | 4,05 | 1,76 | -56,54% |
| 6 | 2016 | 365,26 | 145,87 | -60,06% |
| 7 | 2019 | 2,93 | 1,13 | -61,43% |
| 8 | 2021 | 13,90 | 5,15 | -62,95% |
| 9 | 2022 | 5,15 | 1,25 | -75,73% |
| 10 | 2018 | 16,56 | 2,93 | -82,31% |
| 11 | 2017 | 145,87 | 16,56 | -88,65% |
| Rang | Datum | Vorjahr | Schluss | Performance |
|---|---|---|---|---|
| 1 | 2017 | 145,87 | 16,56 | -88,65% |
| 2 | 2018 | 16,56 | 2,93 | -82,31% |
| 3 | 2022 | 5,15 | 1,25 | -75,73% |
| 4 | 2021 | 13,90 | 5,15 | -62,95% |
| 5 | 2019 | 2,93 | 1,13 | -61,43% |
| 6 | 2016 | 365,26 | 145,87 | -60,06% |
| 7 | 2025 | 4,05 | 1,76 | -56,54% |
| 8 | 2014 | 305,71 | 259,70 | -15,05% |
| 9 | 2023 | 1,25 | 1,27 | 1,60% |
| 10 | 2015 | 259,70 | 365,26 | 40,65% |
| 11 | 2024 | 1,27 | 4,05 | 218,90% |